Advertisement
Research Article| Volume 16, ISSUE 3, P717-729, September 1996

Therapeutic Drug Monitoring of the Antimycobacterial Drugs

  • Charles A. Peloquin
    Correspondence
    Address reprint requests to: Charles A. Peloquin, PharmD, Infectious Disease Pharmacokinetics Laboratory, National Jewish Center for Immunology and Respiratory Medicine, 1400 Jackson Street, Denver, CO 80206
    Affiliations
    From the Infectious Disease Pharmacokinetics Laboratory, National Jewish Center for Immunology and Respiratory Medicine; and the Departments of Pharmacy and Medicine, University of Colorado, Denver, Colorado
    Search for articles by this author
DOI:https://doi.org/10.1016/S0272-2712(18)30263-4
Therapeutic Drug Monitoring of the Antimycobacterial Drugs
Previous ArticleTuberculosis Bacteriology Laboratory Services and Incremental Protocols for Developing Countries
Next ArticleActivities and Recommendations by the Association of State and Territorial Public Health Laboratory Directors
      This paper is only available as a PDF. To read, Please Download here.
      Therapeutic drug monitoring is a process that allows clinicians to quantify and control drug therapy. Serum concentration data can be used to generate various pharmacokinetic and pharmacodynamic parameters. These parameters, in turn, can be used to optimize the doses used for individual patients. The goal is to provide enough drug to obtain a therapeutic response without overt toxicity. The specific application of this process to the antimycobacterial drugs is reviewed.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Berning S.E.
        • Huitt G.A.
        • Iseman M.D.
        • et al.
        Malabsorption of antituberculosis medications by an AIDS patient.
        N Engl J Med. 1992; 327: 1817
        • Comstock G.W.
        • Hammes L.M.
        • Pio A.
        Isoniazid prophylaxis in Alaskan boarding schools. A comparison of two doses.
        Am Rev Respir Dis. 1969; 100: 773
        • Doster B.
        • Murray F.J.
        • Newman R.
        • et al.
        Ethambutol in the initial treatment of pulmonary tuberculosis.
        Am Rev Respir Dis. 1973; 107: 177
        • Evans W.E.
        General principles of applied pharmacokinetics.
        in: Evans WE Schentag JJ Jusko WJ Applied Pharmacokinetics. Principles of Therapeutic Drug Monitoring. ed 3. Applied Therapeutics, Spokane, WA1992: 1
        • Gordon S.M.
        • Horsburgh C.R.
        • Peloquin C.A.
        • et al.
        Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease.
        J Infect Dis. 1993; 168: 1559
        • Heifets L.B.
        Introduction: drug susceptibility tests and the clinical outcome of chemotherapy.
        in: Heifets LB Drug Susceptibility in the Chemotherapy of Mycobacterial Infections. CRC Press, Boca Raton, FL1991: 1
        • Jelliffe R.W.
        • Maire P.
        • Sattler F.
        • et al.
        Adaptive control of drug dosage regimens: Basic foundations, relevant issues, and clinical examples.
        Int J Biomed Comput. 1994; 36: 1
        • Jusko W.J.
        Guidelines for collection and analysis of pharmacokinetic data.
        in: Evans WE Schentag JJ Jusko WJ Applied Pharmacokinetics. Principles of Therapeutic Drug Monitoring. ed 3. Applied Therapeutics, Inc., Spokane, WA1992: 1-2
        • LeBel M.
        • Spino M.
        Pulse dosing versus continuous infusion of antibiotics. Pharmacokinetic-pharmacodynamic considerations.
        Clin Pharmacokinet. 1988; 14: 71
        • Long M.W.
        • Snider Jr D.E.
        • Farer L.S.
        U.S. Public Health Service cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis.
        Am Rev Respir Dis. 1979; 119: 879
        • Peloquin C.A.
        Pharmacology of the antimycobacterial drugs.
        Med Clin North Am. 1993; 77: 1253

      12. Peloquin CA: Antimicrobial therapy. In Bittar EE, Bittar N (eds): Principles of Medical Biology. Greenwich, CT, Jai Press Inc, in press

        • Peloquin C.A.
        Antituberculosis drugs: pharmacokinetics.
        in: Heifets LB Drug Susceptibility in the Chemotherapy of Mycobacterial Infections. CRC Press, Boca Raton, FL1991: 59
        • Peloquin C.A.
        Therapeutic drug monitoring: principles and applications in mycobacterial infections.
        Drug Ther. 1992; 22: 31

      15. Peloquin CA, Iseman MD: Antimycobacterial Agents. In Root RK (ed): Clinical Infectious Diseases: A Practical Approach. New York, Oxford University Press, in press

        • Peloquin C.A.
        • MacPhee A.A.
        • Berning S.E.
        Malabsorption of antimycobacterial medications [letter].
        N Engl J Med. 1993; 329: 1122

      17. Peloquin CA, Nitta AT, Burman WJ, et al: Low anti-tuberculosis drug concentrations in patients with AIDS. Ann Pharmacother, in press

        • Shah V.P.
        • Midha K.K.
        • Dighe S.
        • et al.
        Analytical methods validation: Bioavailability, bioequivalence, and pharmacokinetic studies.
        J Pharm Sci. 1992; 81: 309

      19. Verbist L: Mode of action of antituberculous drugs (parts I and II). Medicon Inti: pll, 3-1-1974 and p 3, 5-2-1974

        • Winder F.G.
        Mode of action of the antimycobacterial agents and associated aspects of the molecular biology of the mycobacteria.
        in: Ratledge C Stanford J The Biology of Mycobacteria, vol 1. Physiology, Identification, and Classification. Academic Press, London1982: 354

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0272-2712(18)30263-4

      Copyright

      © 1996 Elsevier Inc. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX